State webinar participants attending this “safe harbor” discussion heard from the legal and legislative experts who crafted these models to withstand legal challenges and to minimize administrative burden on states.
As six trailblazing states seek federal approval necessary to import prescription drugs from Canada, one new NASHP model law enables states to “import” these lower prices by setting upper payment limits, including biologics that federal law currently prohibit from importation.
A second new model act builds on state drug price transparency laws and goes a step further to impose stiff penalties on manufacturers whose drug price increases are not supported by new clinical evidence. While the Biden administration’s plans are similar, they face Congressional resistance and some are limited to Medicare. Fast action at the state level can bring needed relief from prescription drug prices for all commercial payers and serve as models for how federal approaches could work.
- Trish Riley, Executive Director, NASHP
- Michelle Mello, JD, PhD, Professor, Stanford Law School
- Stacie Dusetzina, PhD, Associate Professor of Health Policy, Vanderbilt University School of Medicine
- Steven Pearson, MD, MSc, Founder and President, Institute for Clinical and Economic Review
- Sarah Emond, MPP, Executive Vice President and Chief Operating Officer, Institute for Clinical and Economic Review,
- Rachel Sachs, JD, MPH, Associate Professor, Washington University School of Law
State Rep. Drew Gattine, JD, Maine House of Representatives